Morphic Holding, Inc. is a biopharmaceutical company applying its proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small molecule integrin therapeutics. The Company created the Morphic integrin technology (MInT) platform by leveraging its unique understanding of integrin structure and biology to develop novel product candidates designed to achieve potency, high selectivity and the pharmaceutical properties required for oral administration. Morphic is advancing its lead wholly-owned program for α4β7-specific integrin inhibitors affecting inflammation into clinical development for the treatment of inflammatory bowel disease, or IBD. Morphic is also developing its most advanced product candidate, MORF-720, a selective oral αvβ6-specific integrin inhibitor into clinical development for the treatment of idiopathic pulmonary fibrosis, or IPF, in collaboration with AbbVie.